Dmitriy Niyazov

Associate Professor

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

With the rapid adoption and increasing use of genetic testing in pediatric neurology, the discovery and characterization of novel pathogenic variants resulting in neurodevelopmental and seizure disorders are becoming more common. One such disorder is EIF4A2‐ related neurodevelopmental disorder, a recently described disorder with various clinical associations, including developmental delay, epilepsy, and structural brain anomalies. In this case series, we describe two patients with pathogenic EIF4A2 variants, including one of the first detailed reports of a patient with EIF4A2 mosaicism, to add to the growing catalog of genotypic variability in this disorder, as well as a novel phenotypic finding of absent cochlear nerve. Both cases presented here involve patients who developed subtle, initially electrographically negative, epileptic spasms before going on to develop characteristic findings of infantile spasms requiring hormonal treatment. Together, these cases provide valuable information to guide future management of patients with EIF4A2 ‐related disorder.

Year:

2026

Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections. MoCD has a distinct biochemical profile, characterized by elevated urinary S ‐sulfocysteine, xanthine, and hypoxanthine, and low or undetectable serum and urine uric acid levels. A disease‐altering treatment is available for MoCD Type A; however, due to the rarity of the condition, its natural history remains poorly understood. We present a patient with neonatal‐onset refractory seizures, whose biochemical testing, performed within 24 h of specimen receipt in the laboratory, revealed a pattern consistent with MoCD. Before the genetics team could disclose the preliminary diagnosis, the patient demised, without evidence of worsening seizures or respiratory infection. Results of genome sequencing, guided by biochemical findings, identified double homozygous pathogenic variants in MOCS1 (associated with MoCD Type A). Although the biochemical genetics laboratory's protocol for analyzing and reporting S ‐sulfocysteine levels within 48 h enabled a rapid preliminary diagnosis, the patient's condition deteriorated too quickly to initiate disease‐altering treatment, progressing more rapidly than described in the literature. We discuss potential hypotheses for his rapid decline and the broader implications for the field of biochemical genetics.

Year:

2026

Neurodevelopmental proteasomopathies represent a distinctive category of neurodevelopmental disorders (NDD) characterized by genetic variations within the 26S proteasome, a protein complex governing eukaryotic cellular protein homeostasis. In our comprehensive study, we identified 23 unique variants in PSMC5 , which encodes the AAA-ATPase proteasome subunit PSMC5/Rpt6, causing syndromic NDD in 38 unrelated individuals. Overexpression of PSMC5 variants altered human hippocampal neuron morphology, while PSMC5 knockdown led to impaired reversal learning in flies and loss of excitatory synapses in rat hippocampal neurons. PSMC5 loss-of-function resulted in abnormal protein aggregation, profoundly impacting innate immune signaling, mitophagy rates, and lipid metabolism in affected individuals. Importantly, targeting key components of the integrated stress response, such as PKR and GCN2 kinases, ameliorated immune dysregulations in cells from affected individuals. These findings significantly advance our understanding of the molecular mechanisms underlying neurodevelopmental proteasomopathies, provide links to research in neurodegenerative diseases, and open up potential therapeutic avenues.

Year:

2024

Collaborators (29)

Ype Elgersma

Full professor

Erasmus MC

NETHERLANDS
View details

Tamar Harel

-

ISRAEL
View details

Geeske van Woerden

Associate professor

Erasmus University Rotterdam

NETHERLANDS
View details

Rebecca Ganetzky

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

EFTERPI PAVLIDOU

Assistant Professor of Pediatrics

University of Ioannina

GREECE
View details

Peter Krawitz

University of Bonn

GERMANY
View details

Dominique Bonneau

Professor of Medical Genetics

Université d'Angers

FRANCE
View details

Arnaud Droit

Professor

Université Laval Faculté de médecine

CANADA
View details

Tzung-Chien Hsieh

University Hospital Bonn

GERMANY
View details

Evan Eichler

Howard Hughes Medical Institute

UNITED STATES
View details

Marie-Pierre Bousquet

Institute of Pharmacology and Structural Biology

FRANCE
View details

Peter Werner Hildebrand

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Stéphane Bézieau

Université de Nantes

FRANCE
View details

Andrew Dauber

The George Washington University School of Medicine and Health SCiences

UNITED STATES
View details

Frederic Laumonnier

Team Leader, Research Director

INSERM

FRANCE
View details

Renske Oegema

UMC Utrecht

NETHERLANDS
View details

Rami Abou Jamra

University Hospital Leipzig

GERMANY
View details

Jens Meiler

Vanderbilt University

UNITED STATES
View details

Kimberly McDonald

Assistant Professor

University of Mississippi Medical Center

UNITED STATES
View details

Elke Hammer

University Medicine Greifswald

GERMANY
View details

Elke Krueger

Director

University Medicine Greifswald

GERMANY
View details

Tychele Turner

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Frédéric Ebstein

Group Leader

Université de Nantes

FRANCE
View details

Andreas Grabrucker

Lecturer (Assist. Prof)

University of Limerick

IRELAND
View details

Gregory Costain

Hospital for Sick Children

CANADA
View details

Antonio Vitobello

Full professor

Université de Bourgogne

FRANCE
View details

Anita Rauch

University of Zurich

SWITZERLAND
View details

Julien Marcoux

CNRS Research Director

Institute of Pharmacology and Structural Biology

FRANCE
View details

Miroslava Hancarova

Charles University

CZECH REPUBLIC
View details